09.15.26 -- Plotting The Timeline For A Tech Transfer In ADC Development

High-concentration biologics can face viscosity and aggregation challenges. Early modeling and targeted testing optimize formulations for stability, manufacturability, and delivery.

How strategic investments in development, manufacturing, and clinical supply are helping organizations reduce risk and accelerate drug development.

Watch as our CGT experts explore the evolving landscape of viral vector manufacturing, overcoming production bottlenecks, and the strategies necessary to bring life-changing therapies to more patients.

Producing bispecific antibodies at scale is notoriously difficult. See how to achieve a 3X yield increase and 98.5% purity with Hinge Bio's GEM-DIMER™ platform in just seven months.

Discover an innovative approach to drug conjugation that expands the range of molecules suitable for targeted therapies while preserving their biological activity and enabling controlled drug release.

Domestic pharmaceutical manufacturing strengthens supply chain resilience, simplifies distribution, speeds market response, and reduces risk by aligning production with key markets.

Unlock the knowledge and strategies you need to navigate the complexities of CGT outsourcing and accelerate the success of your cell and gene therapy projects.

Examine how data‑driven collaboration and animal‑origin‑free media strategies can reduce variability, improve cell culture performance, and support consistent, cost‑effective bioprocessing at scale.

Manufacturing and quality gaps drive most FDA Complete Response Letters in cell therapy, often stemming from early‑stage decisions and unresolved CMC issues that become major approval risks.

This Disposable Pen is a proven, globally adopted drug delivery platform with over 175 million units sold, supporting diverse therapies in 40+ countries.